Pridinol is a centrally acting muscle relaxant. It is used to treat muscle spasms of a central or peripheral nature. It is mainly used for lumbalgia, torticollis and general muscle pain in adults. It is used perorally in the form of tablets or by intramuscular injection.
The drug was approved in Europe in 2018.
Pharmacodynamics
The exact mechanism of action is not yet fully understood. However, pridinol is thought to have an atropine-like effect by blocking acetylcholine receptors in the brain, resulting in relaxation of skeletal muscle.
Pharmacokinetics
Complete absorption after oral administration occurs after about one hour. Pridinol is excreted partly unchanged, partly metabolized and eliminated by the kidney. The plasma half-life is between 14 and 18 hours.
Drug-Drug Interactions
When administered concomitantly with anticholinergics such as atropine, their effect may be considerably enhanced.
Adverse effects
Contraindications
| ATC Code | M03BX03, N04AA14 |
| Formula | C20H25NO |
| Molar Mass (g·mol−1) | 295,42 |
| Physical State | solid |
| Melting Point (°C) | 147–149 |
| CAS Number | 511-45-5 |
| PUB Number | 4904 |
| Drugbank ID | DB13642 |
Ad
